证券代码：688526 证券简称：科前生物 公告编号：2025-038 武汉科前生物股份有限公司 根据《关于上市公司实施员工持股计划试点的指导意见》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法 律法规的相关规定，现将本次员工持股计划的实施进展情况公告如下： 根据参与对象实际认购和最终缴款的审验结果，本次员工持股计 划实际参与认购的员工共计 55 人，认购资金已全部实缴到位，最终 缴纳的认购资金总额为 1,769.2584 万元，认购份额对应股份数量为 股股票。 海分公司出具的《证券过户登记确认书》，公司回购专用证券账户中 所持有的 221.1573 万股公司股票已于 2025 年 8 月 8 日非交易过户至 "武汉科前生物股份有限公司－2025 年员工持股计划"证券账户（证 券账户号码：B887331558），过户价格为 8 元/股。截至本公告披露 日，本次员工持股计划证券账户持有公司股份 221.1573 万股，占公 司当前总股本的比例为 0.4745%。 根据《武汉科前生物股份有限公司 2025 年员工持股计划》的相 关规定，本次员工持股计划的存续期为 48 个月，自本员工持股 ...

Core Viewpoint - The company plans to utilize idle raised funds for cash management, not exceeding RMB 260 million, to enhance fund efficiency while ensuring the normal operation of fundraising projects and maintaining fund safety [1][2][8] Summary by Sections Investment Purpose - The company aims to improve fund efficiency and increase shareholder returns by managing temporarily idle raised funds, ensuring it does not affect the progress of fundraising projects [5][7] Fund Source and Limit - The company will use up to RMB 260 million of idle raised funds for cash management, which can be rolled over within the specified limit [2][5] Investment Duration - The investment period is valid for 12 months from the date of the board's approval [5][6] Investment Method - The company will invest in high-security, liquid products such as structured deposits, time deposits, and large certificates of deposit, ensuring compliance with relevant regulations [5][6] Impact on Daily Operations - The cash management of idle funds will not affect the normal operation of fundraising projects and is expected to enhance overall performance and shareholder returns [7][8] Approval Process - The proposal for cash management has been approved by the board and supervisory board, complying with legal and regulatory requirements [8]

证券代码：688739 证券简称：成大生物 公告编号：2025-041 辽宁成大生物股份有限公司 关于公司董事变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 辽宁成大生物股份有限公司（以下简称"成大生物"或"公司"）董事会于 近日收到董事董丙建先生与崔建伟先生的书面辞职报告。因工作需要，董丙建先 生申请辞去公司董事及董事会战略委员会委员职务，辞职后将不再担任公司任何 职务；崔建伟先生申请辞去公司董事职务，辞职后仍将担任公司副总经理、财务 总监职务。根据公司控股股东辽宁成大股份有限公司推荐、经董事会提名委员会 资格审查通过，董事会同意提名徐飚先生、周岳先生为公司第五届董事会非独立 董事候选人，任期自公司股东会审议通过之日起至第五届董事会届满之日止。该 议案尚需提交公司股东会审议。 公司于 2025 年 8 月 12 日召开第五届董事会第二十一次会议，审议通过了 《关 于补选公司董事的议案》。根据公司控股股东辽宁成大股份有限公司推荐、经董 事会提名委员会资格审查通过，董事会提名徐飚先生、周岳先生为公司第 ...

辽宁成大生物股份有限公司 信息披露管理制度 辽宁成大生物股份有限公司 信息披露管理制度 第一章 总 则 第一条 为提高辽宁成大生物股份有限公司（以下简称"公司"）信息披露工作质 量和规范信息披露行为，确保公司对外信息披露工作的真实性、准确性、及时性，保 护公司、股东、债权人及其他利益相关者的合法权益，根据《中华人民共和国公司法》 （以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司信息披露管理办法》（以下简称"《管理办法》"）《上海证券交易所科 创板股票上市规则》（以下简称"《上市规则》"）及其他有关法律、法规、规范性 文件和《辽宁成大生物股份有限公司章程》（以下简称"《公司章程》"）的规定， 制定本制度。 第二条 本制度所称"信息披露"是指公司将对公司股票及其衍生品种交易价格可 能产生较大影响而投资者尚未得知的信息或影响投资者作出价值判断和投资决策的重 大信息，在规定的期限内，通过上海证券交易所网站和符合中国证监会规定条件的媒 体，以规定的方式向社会公众公布，并按照规定报送证券监管部门。 第三条 本制度适用于如下人员和机构： (一) 公司董事会秘书和信息披露事务管理部门； ...

General Principles - The purpose of the independent director system is to enhance the corporate governance structure of Liaoning Chengda Biological Co., Ltd. and create a favorable working environment for independent directors [1][2] - Independent directors are defined as those who do not hold any other positions in the company and have no direct or indirect interests that could hinder their independent judgment [1][2] Independent Director Responsibilities - Independent directors have a duty of loyalty and diligence to the company and all shareholders, and they must perform their duties in accordance with relevant laws and the company's articles of association [1][2] - They are required to participate in decision-making, supervision, and provide professional advice to protect the overall interests of the company and the legal rights of minority shareholders [1][2] Qualifications and Independence - Independent directors must meet specific qualifications, including having at least five years of relevant work experience and a good personal character without significant credit issues [2][3] - The company must ensure that independent directors maintain their independence and are not influenced by major shareholders or actual controllers [2][3] Nomination and Election - Independent directors can be nominated by the board of directors or shareholders holding more than 1% of the company's issued shares, and their qualifications must be reviewed before nomination [5][6] - The election of independent directors must be conducted separately from non-independent directors, and cumulative voting is required when electing multiple independent directors [6][14] Duties and Powers - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing objective advice to enhance decision-making quality [18][19] - They have special powers, including the ability to hire external consultants, propose meetings, and express independent opinions on matters that may harm the company or minority shareholders [19][20] Communication and Reporting - The company must establish a communication mechanism between independent directors and minority shareholders, allowing independent directors to verify investor inquiries [29] - Independent directors are required to submit annual reports on their performance to the company's annual general meeting [30] Support and Compensation - The company must provide necessary working conditions and support for independent directors to fulfill their responsibilities [32][33] - Independent directors are entitled to compensation that corresponds to their responsibilities, which must be approved by the shareholders' meeting and disclosed in the annual report [38]

Core Viewpoint - The company plans to sign a cooperation research and development agreement with Huazhong Agricultural University, which is expected to enhance its core competitiveness in the bioproducts sector and accelerate its development in the industry [1]. Summary by Relevant Sections - **Cooperation Agreement**: The proposed agreement with Huazhong Agricultural University is seen as beneficial for improving the company's competitiveness in the bioproducts field [1]. - **Compliance and Procedures**: The transaction adheres to the company's articles of association, cooperation research and development management system, and the framework agreement with Huazhong Agricultural University, ensuring that all procedures are followed [1]. - **Related Party Transaction**: This transaction is classified as a related party transaction, with legal voting procedures and fair pricing, ensuring no harm to the company or its shareholders [1].

辽宁成大生物股份有限公司 投资者关系管理制度 辽宁成大生物股份有限公司 投资者关系管理制度 第一章 总则 第一条 为加强辽宁成大生物股份有限公司（以下简称"公司"）与投资者和 潜在投资者（以下简称"投资者"）之间的信息沟通，增进投资者对公司的了解与 认同，切实维护广大投资者的合法权益，完善公司的治理结构，根据《中华人民共 和国公司法》 （以下简称"《公司法》"） 《中华人民共和国证券法》 （以下简称"《证 券法》"） 《上市公司治理准则》 《上市公司投资者关系管理工作指引》 《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》等法律、法规和规范性文件的规定及《辽宁成大生物股份有限公司 章程》（以下简称"《公司章程》" ），结合公司实际情况，制定本制度。 第二条 本制度所称投资者关系管理是指公司通过便利股东权利行使、信息披 露、互动交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投 资者对公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 第三条 公司投资者关系管理工作应严格遵守《公司法 ...

辽宁成大生物股份有限公司 募集资金管理制度 第一章 总则 辽宁成大生物股份有限公司 募集资金管理制度 公司董事会办公室负责与募集资金管理、使用及变更有关的信息披露；财务 部门负责募集资金的日常管理，包括专用账户的开立及管理，募集资金的存放、 使用和台账管理。 第五条 公司控股股东、实际控制人不得直接或者间接占用或者挪用公司募 集资金，不得利用公司募投项目获取不正当利益。 公司发现控股股东、实际控制人及其他关联人占用募集资金的，应当及时要 求归还，并披露占用发生的原因、对公司的影响、清偿整改方案及整改进展情况。 第一条 为规范辽宁成大生物股份有限公司（以下简称"公司"）募集资金 的使用与管理，提高募集资金使用效益，保护投资者的合法权益，根据《中华人 民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公司治理准则》《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律、法规和规范性文件的规定及《辽宁成大 生物股份有限公司章程》（以下简称"《公司章程》"），结合公司实际情况， 制定 ...

辽宁成大生物股份有限公司 董事、高级管理人员持股变动管理办法 董事、高级管理人员持股变动管理办法 第一章 总则 第一条 为加强辽宁成大生物股份有限公司（以下简称"公司"或"本公司"） 对董事、高级管理人员持有及买卖本公司股份的管理工作，根据《中华人民共和 国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称 "《证券法》"）《上市公司股东减持股份管理暂行办法》《上市公司董事和高 级管理人员所持本公司股份及其变动管理规则》《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》《上海证券交易所上市公司自律监管指引 第 8 号——股份变动管理》《上海证券交易所上市公司自律监管指引第 15 号— —股东及董事、高级管理人员减持股份》等法律、行政法规、部门规章、规范性 文件及《辽宁成大生物股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，结合公司实际情况，制定本办法。 第二条 本办法适用于公司董事、高级管理人员所持本公司股份及其变动的 管理。 公司董事、高级管理人员所持本公司股份，是指登记在其名下和利用他人账 户持有的所有本公司股份。董事、高级管理人员拥有多个证券账户的，应当合 ...

Core Viewpoint - The document outlines the external guarantee management system of Liaoning Chengda Biological Co., Ltd., aiming to standardize external guarantee behaviors and effectively prevent related risks [1][2]. Chapter Summaries Chapter 1: General Principles - The system is established based on various laws and regulations to regulate the company's external guarantee behavior [1]. Chapter 2: Guarantee Principles - External guarantees refer to the company and its subsidiaries providing guarantees based on legal agreements, adhering to principles of fairness, voluntariness, and mutual benefit [2]. - The scope of this system includes the company and its subsidiaries [1]. Chapter 3: Guarantee Approval Management - All guarantees must be managed centrally by the company, requiring approval from the board of directors or shareholders before any guarantee is provided [2][3]. - Guarantees for related parties must have reasonable commercial logic and require disclosure and shareholder approval [2]. Chapter 4: Contract Signing - After board or shareholder approval, the chairman or other senior management is authorized to sign guarantee contracts [4][6]. - Guarantee contracts must comply with legal norms and clearly define the terms [6]. Chapter 5: Guarantee Risk Management - The board and finance department are responsible for managing and reviewing guarantee behaviors [7]. - Any abnormal contracts not approved by the board must be reported immediately [7]. Chapter 6: Accountability - Directors and managers who violate the established procedures for signing guarantee contracts may face economic and legal consequences [8]. - Individuals who fail to perform their duties, causing losses to the company, may be subject to penalties [8]. Chapter 7: Supplementary Provisions - Any matters not covered by this system or conflicting with legal requirements will be executed according to relevant laws and regulations [8].